Indivior Pharmaceuticals Inc (INDV) — Analyst outlook / Analyst consensus target is. Based on 3 analyst ratings, the consensus is bullish — 3 Buy.
The consensus price target is $43.75 (low: $36.00, high: $50.00), representing an upside of 32.7% from the current price $32.97.
Analysts estimate Earnings Per Share (EPS) of $1.66 and revenue of $1.15B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $0.02 vs est $1.66 (missed -98.8%). 2025: actual $1.68 vs est $2.35 (missed -28.6%). Analyst accuracy: 0%.
INDV Stock — 12-Month Price Forecast
$43.75
▲ +32.70% Upside
Average Price Target
Based on 3 Wall Street analysts offering 12-month price targets for Indivior Pharmaceuticals Inc, the average price target is $43.75, with a high forecast of $50.00, and a low forecast of $36.00.
The average price target represents a +32.70% change from the last price of $32.97.
Highest Price Target
$50.00
Average Price Target
$43.75
Lowest Price Target
$36.00
INDV Analyst Ratings
Buy
Based on 3 analysts giving stock ratings to Indivior Pharmaceuticals Inc in the past 3 months
EPS Estimates — INDV
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.02
vs Est $1.66
▼ 8,187.0% off
2025
Actual $1.68
vs Est $2.35
▼ 40.1% off
Profitability Outlook
Company is profitable but with thin earnings per share. EPS trend is improving.
Revenue Estimates — INDV
96%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $1.188B
vs Est $1.151B
▲ 3.1% off
2025
Actual $1.239B
vs Est $1.191B
▲ 3.9% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
